시장보고서
상품코드
1426855

세계의 항암제 시장(2024년)

Global Anticancer Drugs Market Research Report 2024

발행일: | 리서치사: QYResearch | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

세계의 항암제 시장 규모는 2023년에 1,900억 1,200만 달러에 달했습니다. 이 시장은 2024-2030년의 예측 기간 중 11.26%의 CAGR로 확대하며, 2030년에는 3,910억 300만 달러에 달할 것으로 예측되고 있습니다.

북미의 항암제 시장 규모는 2023년 1,048억 3,500만 달러에서 2030년에는 2,070억 6,800만 달러에 달할 것으로 예측되며, 2024-2030년의 예측 기간 중 CAGR은 10.7%에 달할 것으로 전망됩니다.

아시아태평양의 항암제 시장 규모는 2023년 395억 1,800만 달러에서 2030년에는 890억 4,200만 달러에 달할 것으로 예측되며, 2024-2030년의 예측 기간 중 CAGR은 12.38%에 달할 것으로 전망됩니다.

항암제의 세계 주요 제조업체에는 Merck & Co, Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, AstraZeneca, Pfizer, Amgen, Eli Lilly 등이 있습니다. 2023년, 세계 상위 5사의 판매고 점유율은 약 55.06%였습니다.

세계의 항암제 시장에 대해 조사했으며, 시장의 개요와 기업별, 유형별, 용도별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 항암제 시장 개요

  • 제품의 정의
  • 항암제, 유형별
  • 항암제, 용도별
  • 세계의 항암제 시장 규모 예측
  • 전제와 제한

제2장 제조업체에 의한 항암제 시장 경쟁

제3장 세계의 항암제 시장 시나리오, 지역별

  • 세계의 항암제 시장 규모 : 2019년 대 2023년 대 2030년, 지역별
  • 지역별 세계의 항암제 매출 : 2019-2030년
  • 북미
  • 유럽
  • 아시아태평양
  • 남미
  • 중동 및 아프리카

제4장 유형별 부문

  • 세계의 항암제 매출(2019-2024년), 유형별
  • 세계의 항암제 매출(2025-2030년), 유형별
  • 세계의 항암제 매출 시장 점유율(2019-2030년), 유형별

제5장 용도별 부문

  • 세계의 항암제 매출(2019-2024년), 용도별
  • 세계의 항암제 매출(2025-2030년), 용도별
  • 세계의 항암제 매출 시장 점유율(2019-2030년), 용도별

제6장 주요 기업의 개요

  • Abbvie
  • Johnson & Johnson
  • Novartis
  • Gilead Sciences
  • Roche
  • Bristol-Myers Squibb
  • Amgen
  • AstraZeneca
  • Merck & Co
  • Takeda
  • Merck KGaA
  • Seagen
  • Eli Lilly
  • Ono Pharmaceutical
  • Pfizer
  • GSK
  • Exelixis
  • Regeneron
  • Innovent
  • Innovent

제7장 산업 체인과 판매채널 분석

  • 항암제 산업 체인 분석
  • 항암제의 주요 원료
  • 항암제의 제조 방법과 프로세스
  • 항암제 판매 및 마케팅
  • 항암제 고객

제8장 항암제 시장 역학

  • 항암제 업계의 동향
  • 항암제 시장 촉진요인
  • 항암제 시장이 해결해야 할 과제
  • 항암제 시장 억제요인

제9장 조사 결과와 결론

제10장 조사 방법과 데이터 소스

KSA 24.02.26

The global Anticancer Drugs market was valued at US$ 190,012 million in 2023 and is anticipated to reach US$ 391,003 million by 2030, witnessing a CAGR of 11.26% during the forecast period 2024-2030.

North American market for Anticancer Drugs is estimated to increase from $ 104,835 million in 2023 to reach $ 207,068 million by 2030, at a CAGR of 10.7% during the forecast period of 2024 through 2030.

Asia-Pacific market for Anticancer Drugs is estimated to increase from $ 39,518 million in 2023 to reach $ 89,042 million by 2030, at a CAGR of 12.38% during the forecast period of 2024 through 2030.

The global key manufacturers of Anticancer Drugs include Merck & Co, Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, AstraZeneca, Pfizer, Amgen, Eli Lilly, etc. In 2023, the global top five players had a share approximately 55.06% in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Anticancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anticancer Drugs.

The Anticancer Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anticancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Anticancer Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • AbbVie
  • Johnson & Johnson
  • Novartis
  • Gilead Sciences
  • Roche
  • Bristol-Myers Squibb
  • Amgen
  • AstraZeneca
  • Merck & Co
  • Takeda
  • Merck KGaA
  • Seagen
  • Eli Lilly
  • Ono Pharmaceutical
  • Pfizer
  • GSK
  • Exelixis
  • Regeneron
  • Innovent
  • Hengrui Medicine

Segment by Type

  • Chemotherapy
  • Targeted Therapy
  • Cancer Immunotherapy
  • Other

Segment by Application

  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood-related Cancer
  • Other

Consumption by Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Southeast Asia
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Rest of Europe
  • South America
  • Brazil
  • Middle East & Africa
  • Middle East
  • Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Detailed analysis of Anticancer Drugs manufacturers competitive landscape revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Revenue of Anticancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 9: The main points and conclusions of the report.

Table of Contents

1 Anticancer Drugs Market Overview

  • 1.1 Product Definition
  • 1.2 Anticancer Drugs by Type
    • 1.2.1 Global Anticancer Drugs Market Value Comparison by Type (2024-2030)
    • 1.2.2 Chemotherapy
    • 1.2.3 Targeted Therapy
    • 1.2.4 Cancer Immunotherapy
  • 1.3 Anticancer Drugs by Application
    • 1.3.1 Global Anticancer Drugs Market Value by Application (2024-2030)
    • 1.3.2 Lung Cancer
    • 1.3.3 Breast Cancer
    • 1.3.4 Prostate Cancer
    • 1.3.5 Blood-related Cancer
  • 1.4 Global Anticancer Drugs Market Size Estimates and Forecasts
  • 1.5 Assumptions and Limitations

2 Anticancer Drugs Market Competition by Manufacturers

  • 2.1 Global Anticancer Drugs Revenue Market Share by Manufacturers (2019-2024)
  • 2.2 Global Key Players of Anticancer Drugs, Industry Ranking, 2022 VS 2023 VS 2024
  • 2.3 Global Key Manufacturers of Anticancer Drugs, Market Area & Headquarters
  • 2.4 Global Key Manufacturers of Anticancer Drugs, Product Type
  • 2.5 Global Key Manufacturers of Anticancer Drugs, Founded Date
  • 2.6 Global Anticancer Drugs Market Competitive Situation and Trends
    • 2.6.1 Global Anticancer Drugs Market Concentration Rate
    • 2.6.2 The Global 5 and 10 Largest Anticancer Drugs Players Market Share by Revenue
    • 2.6.3 Global Anticancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 2.7 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Anticancer Drugs Market Scenario by Region

  • 3.1 Global Anticancer Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
  • 3.2 Global Anticancer Drugs Revenue by Region: 2019-2030
    • 3.2.1 Global Anticancer Drugs Revenue by Region: 2019-2024
    • 3.2.2 Global Anticancer Drugs Revenue by Region: 2025-2030
  • 3.3 North America Anticancer Drugs Market Facts & Figures by Country
    • 3.3.1 North America Anticancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
    • 3.3.2 North America Anticancer Drugs Revenue by Country (2019-2030)
    • 3.3.3 U.S.
    • 3.3.4 Canada
    • 3.3.5 Mexico
  • 3.4 Europe Anticancer Drugs Market Facts & Figures by Country
    • 3.4.1 Europe Anticancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
    • 3.4.2 Europe Anticancer Drugs Revenue by Country (2019-2030)
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Anticancer Drugs Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Anticancer Drugs Market Size by Region: 2019 VS 2023 VS 2030
    • 3.5.2 Asia Pacific Anticancer Drugs Revenue by Region (2019-2030)
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Southeast Asia
  • 3.6 South America Anticancer Drugs Market Facts & Figures by Country
    • 3.6.1 South America Anticancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
    • 3.6.2 South America Anticancer Drugs Revenue by Country
    • 3.6.3 Brazil
  • 3.7 Middle East and Africa Anticancer Drugs Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Anticancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
    • 3.7.2 Middle East and Africa Anticancer Drugs Revenue by Country
    • 3.7.3 Middle East
    • 3.7.4 Africa

4 Segment by Type

  • 4.1 Global Anticancer Drugs Revenue by Type (2019-2024)
  • 4.2 Global Anticancer Drugs Revenue by Type (2025-2030)
  • 4.3 Global Anticancer Drugs Revenue Market Share by Type (2019-2030)

5 Segment by Application

  • 5.1 Global Anticancer Drugs Revenue by Application (2019-2024)
  • 5.2 Global Anticancer Drugs Revenue by Application (2025-2030)
  • 5.3 Global Anticancer Drugs Revenue Market Share by Application (2019-2030)

6 Key Companies Profiled

  • 6.1 Abbvie
    • 6.1.1 Abbvie Details
    • 6.1.2 Abbvie Major Business
    • 6.1.3 Abbvie Anticancer Drugs Product and Solutions
    • 6.1.4 Abbvie Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.1.5 Abbvie Recent Developments and Future Plans
  • 6.2 Johnson & Johnson
    • 6.2.1 Johnson & Johnson Details
    • 6.2.2 Johnson & Johnson Major Business
    • 6.2.3 Johnson & Johnson Anticancer Drugs Product and Solutions
    • 6.2.4 Johnson & Johnson Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.2.5 Johnson & Johnson Recent Developments and Future Plans
  • 6.3 Novartis
    • 6.3.1 Novartis Details
    • 6.3.2 Novartis Major Business
    • 6.3.3 Novartis Anticancer Drugs Product and Solutions
    • 6.3.4 Novartis Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.3.5 Novartis Recent Developments and Future Plans
  • 6.4 Gilead Sciences
    • 6.4.1 Gilead Sciences Details
    • 6.4.2 Gilead Sciences Major Business
    • 6.4.3 Gilead Sciences Anticancer Drugs Product and Solutions
    • 6.4.4 Gilead Sciences Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.4.5 Gilead Sciences Recent Developments and Future Plans
  • 6.5 Roche
    • 6.5.1 Roche Details
    • 6.5.2 Roche Major Business
    • 6.5.3 Roche Anticancer Drugs Product and Solutions
    • 6.5.4 Roche Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.5.5 Roche Recent Developments and Future Plans
  • 6.6 Bristol-Myers Squibb
    • 6.6.1 Bristol-Myers Squibb Details
    • 6.6.2 Bristol-Myers Squibb Major Business
    • 6.6.3 Bristol-Myers Squibb Anticancer Drugs Product and Solutions
    • 6.6.4 Bristol-Myers Squibb Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.6.5 Bristol-Myers Squibb Recent Developments and Future Plans
  • 6.7 Amgen
    • 6.7.1 Amgen Details
    • 6.7.2 Amgen Major Business
    • 6.7.3 Amgen Anticancer Drugs Product and Solutions
    • 6.7.4 Amgen Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.7.5 Amgen Recent Developments and Future Plans
  • 6.8 AstraZeneca
    • 6.8.1 AstraZeneca Details
    • 6.8.2 AstraZeneca Major Business
    • 6.8.3 AstraZeneca Anticancer Drugs Product and Solutions
    • 6.8.4 AstraZeneca Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.8.5 AstraZeneca Recent Developments and Future Plans
  • 6.9 Merck & Co
    • 6.9.1 Merck & Co Details
    • 6.9.2 Merck & Co Major Business
    • 6.9.3 Merck & Co Anticancer Drugs Product and Solutions
    • 6.9.4 Merck & Co Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.9.5 Merck & Co Recent Developments and Future Plans
  • 6.10 Takeda
    • 6.10.1 Takeda Details
    • 6.10.2 Takeda Major Business
    • 6.10.3 Takeda Anticancer Drugs Product and Solutions
    • 6.10.4 Takeda Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.10.5 Takeda Recent Developments and Future Plans
  • 6.11 Merck KGaA
    • 6.11.1 Merck KGaA Details
    • 6.11.2 Merck KGaA Major Business
    • 6.11.3 Merck KGaA Anticancer Drugs Product and Solutions
    • 6.11.4 Merck KGaA Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.11.5 Merck KGaA Recent Developments and Future Plans
  • 6.12 Seagen
    • 6.12.1 Seagen Details
    • 6.12.2 Seagen Major Business
    • 6.12.3 Seagen Anticancer Drugs Product and Solutions
    • 6.12.4 Seagen Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.12.5 Seagen Recent Developments and Future Plans
  • 6.13 Eli Lilly
    • 6.13.1 Eli Lilly Details
    • 6.13.2 Eli Lilly Major Business
    • 6.13.3 Eli Lilly Anticancer Drugs Product and Solutions
    • 6.13.4 Eli Lilly Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 6.14 Ono Pharmaceutical
    • 6.14.1 Ono Pharmaceutical Details
    • 6.14.2 Ono Pharmaceutical Major Business
    • 6.14.3 Ono Pharmaceutical Anticancer Drugs Product and Solutions
    • 6.14.4 Ono Pharmaceutical Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.14.5 Ono Pharmaceutical Recent Developments and Future Plans
  • 6.15 Pfizer
    • 6.15.1 Pfizer Details
    • 6.15.2 Pfizer Major Business
    • 6.15.3 Pfizer Anticancer Drugs Product and Solutions
    • 6.15.4 Pfizer Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.15.5 Pfizer Recent Developments and Future Plans
  • 6.16 GSK
    • 6.16.1 GSK Details
    • 6.16.2 GSK Major Business
    • 6.16.3 GSK Anticancer Drugs Product and Solutions
    • 6.16.4 GSK Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.16.5 GSK Recent Developments and Future Plans
  • 6.17 Exelixis
    • 6.17.1 Exelixis Details
    • 6.17.2 Exelixis Major Business
    • 6.17.3 Exelixis Anticancer Drugs Product and Solutions
    • 6.17.4 Exelixis Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
    • 6.17.5 Exelixis Recent Developments and Future Plans
  • 6.18 Regeneron
    • 6.18.1 Regeneron Details
    • 6.18.2 Regeneron Major Business
    • 6.18.3 Regeneron Anticancer Drugs Product and Solutions
    • 6.18.4 Regeneron Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 6.19 Innovent
    • 6.19.1 Innovent Details
    • 6.19.2 Innovent Major Business
    • 6.19.3 Innovent Anticancer Drugs Product and Solutions
    • 6.19.4 Innovent Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 6.20 Hengrui Medicine
    • 6.20.1 Hengrui Medicine Details
    • 6.20.2 Hengrui Medicine Major Business
    • 6.20.3 Hengrui Medicine Anticancer Drugs Product and Solutions
    • 6.20.4 Hengrui Medicine Anticancer Drugs Revenue, Gross Margin and Market Share (2019-2024)

7 Industry Chain and Sales Channels Analysis

  • 7.1 Anticancer Drugs Industry Chain Analysis
  • 7.2 Anticancer Drugs Key Raw Materials
    • 7.2.1 Key Raw Materials
    • 7.2.2 Raw Materials Key Suppliers
  • 7.3 Anticancer Drugs Production Mode & Process
  • 7.4 Anticancer Drugs Sales and Marketing
    • 7.4.1 Anticancer Drugs Sales Channels
    • 7.4.2 Anticancer Drugs Distributors
  • 7.5 Anticancer Drugs Customers

8 Anticancer Drugs Market Dynamics

  • 8.1 Anticancer Drugs Industry Trends
  • 8.2 Anticancer Drugs Market Drivers
  • 8.3 Anticancer Drugs Market Challenges
  • 8.4 Anticancer Drugs Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

  • 10.1 Methodology/Research Approach
    • 10.1.1 Research Programs/Design
    • 10.1.2 Market Size Estimation
    • 10.1.3 Market Breakdown and Data Triangulation
  • 10.2 Data Source
    • 10.2.1 Secondary Sources
    • 10.2.2 Primary Sources
  • 10.3 Author List
  • 10.4 Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제